Reata Pharmaceuticals Культура компании

Mr. Jason D. Wilson serves as the Chief Financial Officer and Vice President of Strategy at Reata Pharmaceuticals, Inc. Mr. Wilson oversees corporate strategy, finance, accounting and treasury, human resources, business development, investor relations and information technology. He served as Vice President of Finance and Controller of Reata Pharmaceuticals, Inc. He served as Vice President of Caris Life Sciences, Inc. Since joining Pathology Partners, Inc. Mr. Wilson joined Reata in 2006. He held over 14 years financial management and accounting experience in life sciences-related businesses. From 2006 to 2006, he served as the Vice President, Finance and Corporate Controller at Miraca Life Sciences, Inc. (formerly, Caris Life Sciences, Inc. and Pathology Partners, Inc.). He served as Corporate Controller of Caris Life Sciences, Inc. since January 2003. Mr. Wilson has helped to implement an improved internal control structure including the writing of new policies and procedures, implementation of additional control mechanisms and the creation of an overall control framework. Additionally, he has helped to streamline the accounting and reporting process, decreasing the time needed to report information to management and investors. Prior to joining Pathology Partners, Mr. Wilson served as a Senior Manager in Health Sciences and Emerging Growth Market practices at Ernst & Young LLP, worked with publicly traded and entrepreneurial companies. During his more than nine years in public accounting, Mr. Wilson developed an extensive knowledge base in SEC reporting, internal control structure and technical researching. Mr. Wilson is a Certified Public Accountant. He holds BBA in Accounting from Henderson University. He holds M.B.A. from University of Central Arkansas.

Dr. Keith W. Ward, Ph.D. serves as Chief Development Officer and Vice President at Reata Pharmaceuticals, Inc. Dr. Ward oversees research and development, clinical operations, regulatory affairs and project management at Reata Pharmaceuticals, Inc. Dr. Ward served as Vice President of Early Development of Reata Pharmaceuticals, Inc. Dr. Ward was responsible for activities from lead optimization through early clinical development, including translational pharmacology. Dr. Ward joined Reata in July 2011. Prior to joining Reata, Dr. Ward developed pharmaceuticals and medical devices as Global Vice President of Pharmaceutical R&D for Bausch & Lomb Incorporated from May 2005 to June 2011. Prior to joining Reata, he developed ophthalmic pharmaceuticals and medical devices in positions of increasing responsibility for Bausch & Lomb Incorporated. Dr. Ward served positions of increasing responsibility within GlaxoSmithKline and SmithKline Beecham Pharmaceuticals. Dr. Ward has extensively published in the area of preclinical development, particularly the refinement of translational models and the use of in vivo preclinical data to drive lead optimization and candidate selection in drug discovery. Dr. Ward earned a B.S. in Toxicology from Northeast Louisiana University and a Ph.D. in Toxicology from The University of North Carolina at Chapel Hill.

Dr. Colin J. Meyer, M.D. serves as the Chief Medical Officer and Vice President of Product Development at Reata Pharmaceuticals, Inc. Dr. Meyer served as Director for Preclinical Programs and Regulatory Affairs of Reata Pharmaceuticals, Inc. Dr. Meyer joined Reata as its second employee. His primary responsibility is to develop strategies to move early, preclinical drug candidates into clinical testing. His duties include designing and overseeing efficacy and toxicology testing in preclinical models, managing bulk drug and drug product manufacturing and developing regulatory strategies for the drug candidates. He received a B.S. in chemistry with specialization in biochemistry and a B.A. in biology from the University of Virginia. He received an M.D. from the University of Texas Southwestern Medical School and an M.B.A. from Southern Methodist University Cox School of Business.

Ms. Dawn Carter Bir has been Chief Commercial Officer and Vice President of Reata Pharmaceuticals, Inc. since October 11, 2016. Ms. Bir joins Reata Pharmaceuticals with over 20 years of biopharmaceutical sales and marketing experience. Over the past decade she served in senior leadership roles at Pharmacyclics, LLC, McKesson Corporation and Genentech, Inc. Most recently, Ms. Bir served as Vice President of US Sales at Pharmacyclics, LLC where she built and led their first hematology national sales organization of sales representatives, division managers and regional sales directors, responsible for the launch of IMBRUVICA in the US and Puerto Rico. In only 18 months, her team became an industry-recognized commercial sales presence and executed a history-making oncology launch. Prior to joining Pharmacyclics, LLC, she served as Vice President Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals and RxPak. Ms. Bir received a B.S. in Biology from Binghamton University, Binghamton, NY.

Mr. Michael D. Wortley, also known as Mike, has been the Chief Legal Officer and Vice President of Reata Pharmaceuticals, Inc. since April 2015. Mr. Wortley is Administrative Partner of the Vinson & Elkins's Dallas, Texas, office and Co-Section Head of the Vinson & Elkins's Corporate Finance and Securities Section. Mr. Wortley has over 35 years of corporate law experience, focusing on corporate governance matters and mergers and acquisitions, including 25 years in management positions. His clients include issuers, underwriters and investors in public and private securities transactions, including public and private equity and debt offerings (firm commitment, best efforts and shelf offerings); venture capital transactions; and roll-up transactions involving partnerships and corporations. He was a Partner and Lawyer of Vinson & Elkins LLP from 1995 to 2014 and served as its Chief Operating Officer. Mr. Wortley's primary area of practice is corporate and securities law. Mr. Wortley served as an Attorney at Vinson & Elkins LLP from 1995 to March 2015, served as its Chief Operating Partner. He was Managing Partner of the Dallas office and at Johnson & Wortley, P.C. prior to 1995, served as its Chairman of the Board and President. He was Managing Director and Chairman of Johnson & Wortley, P.C from 1991 to 1993. He regularly advises and counsels boards of directors and executives in connection with sensitive corporate matters and transactions, including takeover defenses, employment matters, acquisition inquiries, fiduciary duties, executive compensation, press releases and other documents and financings and restructurings. He represented a public company in its sale through an auction process to private equity funds. He represented a private equity fund in its sale of a healthcare company and represented a private equity fund in its acquisition of the third largest red meat business in the U.S. He represented a private equity fund in six leveraged buyouts in one year and represented a private equity fund's radio company that became by station count the largest owner of radio stations in the U.S. in over 50 acquisitions. He represented a large independent oil and gas company in its acquisition of another public independent oil and gas company and represented the largest manufacturer of tile in its sale to another public company. He represented the largest Hispanic radio company in its acquisition by the largest Hispanic television company and represented a client in the hostile takeover of a non-U.S., publicly-traded oil and gas company. He represented an independent oil and gas company in a merger that, at the time, created the third largest U.S. independent public oil and gas company. He represented a U.S. independent public oil and gas company in an acquisition of a public Canadian oil and gas company. He Represented a client in an investment in four publicly-traded REITS. He represented the same client in the business combination of the four REITS and represented a client in the acquisition of a publicly-traded REIT. He represented a publicly-traded REIT in its sale to another publicly-traded REIT. He has been an Independent Director of Pioneer Natural Resources Company since June 2015. A leader in his community as well, he serves on the board of directors of the Vogel Alcove Childcare Center for the Homeless. He serves as Member of American Bar Association and Dallas Bar Association. As a result of his work on behalf of clients, Mike has been recognized by Chambers Global as a top lawyer in corporate/mergers & acquisitions in each of the last five years (2002-2007), and by The Best Lawyers in America as a leader in corporate law the last four years from 2003 to 2007. He was Admitted to practice: Texas, 1978. Mr. Wortley holds BA in Political Science in 1970 from Southern Methodist University, JD from Southern Methodist University in 1978 and Master of Arts in Regional Planning from University of North Carolina at Chapel Hill in 1973.

Christian Wigley serves as the Vice President, Research of Reata Pharmaceuticals, Inc.. Christian started at Reata Pharmaceuticals, Inc. in Oct of 2003. Christian currently resides in the Dallas/Fort Worth Area.

Edmund Doherty serves as the Vice President Medical Affairs of Reata Pharmaceuticals, Inc.. Edmund started at Reata Pharmaceuticals, Inc. in Jul of 2017. Edmund currently resides in the Dallas/Fort Worth Area.

Vinny Jindal serves as the Vice President Strategy of Reata Pharmaceuticals, Inc.. Vinny started at Reata Pharmaceuticals, Inc. in Nov of 2016. Vinny currently resides in the Dallas/Fort Worth Area.